The first c-Met inhibitor approved by the FDA to market
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patients with locally advanced or metastatic MET exon 14 jumping (METEX 14) mutations in non-small cell lung cancer (NSCLC).). The FDA also approved FoundationOne CDx (F1CDx) as a companion diagnostic product for Tabrecta.
Lung cancer is the most common type of cancer in the world. There were 2.1 million newly diagnosed lung cancer patients in the world in 2018, including 1.8 million deaths. Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), NSCLC accounts for about 85% of lung cancer patients, MET exon 14 jump mutation occurs in 3% -4% of newly diagnosed advanced NSCLC cases.